The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2024 | Challenges associated with maximizing ICI performance in pancreatic tumor treatment
Karen Geboes, MD, PhD, UZ Gent – University Hospital Ghent, Ghent, Belgium, reviews the current efforts made towards the diagnosis and treatment of patients with pancreatic cancer. There is less data available on the efficacy of checkpoint inhibition treatments for pancreatic cancers compared to gastrointestinal cancers. The intricate position of tumors in the stromal structure of the pancreas also makes it difficult to develop tumor-specific immunotherapies and treatment regimens. Further trials aim to improve access to pancreatic tumors and identify patients with high MSI (microsatellite instability) levels. This interview took place at the 39th Annual Meeting SITC 2024 at Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
